Dibotermin Alfa: 4 agencies, 2006–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where dibotermin alfa met resistance it was usually narrowed rather than refused: 3 of 7 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The file has been open for more than a decade: 14.2 years separate the first record, 10 May 2006 at HAS (France), from the most recent, 22 Jul 2020 at HAS (France).
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
HAS (France) was first to assess dibotermin alfa, on 10 May 2006; AWMSG (Wales) did not open a file until 28 Jan 2015 — an unusually long tail of 8.7 years between the earliest and latest system to look at it.
Restriction is doing real work here: 3 of 7 decisive outcomes narrowed dibotermin alfa to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
2 of the 4 agencies here assessed dibotermin alfa more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed dibotermin alfa.
The full ledger for dibotermin alfa reads 3 recommended, 3 restricted, 1 not recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 22 Jul 2020 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| TLV (Sweden) | 23 Feb 2018 | InductOs ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 28 Jan 2015 | For single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative dis… | outside AWMSG criteria | source |
| TLV (Sweden) | 25 Nov 2014 | InductOs ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 7 May 2007 | Acute tibia fractures in adults | accepted (restricted) | source |
3 further decisions for dibotermin alfa, across 1 agency, are not shown here.
Related molecules
- denosumab — same ATC class M05B — Bone diseases
- burosumab — same ATC class M05B — Bone diseases
- romosozumab — same ATC class M05B — Bone diseases
- zoledronic acid — same ATC class M05B — Bone diseases
- vosoritide — same ATC class M05B — Bone diseases
- ibandronic acid — same ATC class M05B — Bone diseases
Coverage: 8 decisions for dibotermin alfa from 4 agencies, 2006 to 2020. Data to 7 Sep 2026. ATC class M05B — Bone diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.